Actavis plc announced that the FDA has approved its supplemental new drug application (sNDA) for Saphris (asenapine) as monotherapy for...
Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. announced that the company is acquiring exclusive rights...
The FDA has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for Saphris (asenapine) for the acute treatment of...
EMA has approved the Marketing Authorization Application for Sycrest (asenapine) sublingual tablets from Merck Inc./MSD for the treatment of moderate...
Sycrest (asenapine)from Lundbeck is launched in the UK for treatment of moderate to severe manic episodes associated with Bipolar Disorder...
Sycrest (asenapine) from Lundbeck is launched in the UK for treatment of moderate to severe manic eposodes associated with Bipolar Disorder in...
Gedeon Richter Plc and Allergan Plc announced that the FDA notified the companies that it will require a three-month extension...